This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Dr Sunir Garg reflects on the recent American Academy of Ophthalmology meeting in Orlando and expresses excitement on how artificial intelligence (AI) can be used to detect, treat, and transform the ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Back ...

"Monogenic" diseases, triggered by mutations in just one gene, may actually be more complex than scientists thought.

The Korea Research Institute of Standards and Science (KRISS) has developed a retina-mimicking eye phantom that faithfully replicates the structural layers and microvascular network of the human ...

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye. A one-time treatment with Luxturna, the first ...

Population-based studies have shown retinal disorders are the most common cause of irreversible blindness in developed countries and the second most common cause of blindness after cataracts in ...

In a genetic association study, investigators integrated data from genome-wide association studies of various disorders with retinal transcriptomic data. Findings revealed that the polygenic risk of ...

The study showed that nanoparticles injected into the retina can successfully stimulate the visual system and restore vision in mice with retinal diseases. The findings suggest that a new type of ...